SMT202000675T1 - Terapia di combinazione implicante anticorpi contro claudina 18.2 per il trattamento del cancro - Google Patents

Terapia di combinazione implicante anticorpi contro claudina 18.2 per il trattamento del cancro

Info

Publication number: SMT202000675T1
Authority: SM; San Marino
Prior art keywords: cancer; treatment; combination therapy; antibodies against; therapy involving
Prior art date: 2012-05-23

Application number

SM20200675T

Other languages

English (en)

Inventor

Ugur Sahin

Özlem Türeci

Rita Mitnacht-Kraus

Stefan Denis Jacobs

Magdalena Jadwiga Utsch

Cornelia Adriana Maria Heinz

Christiane Regina Stadler

Original Assignee

Astellas Pharma Inc

Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-23

Filing date

2013-05-21

Publication date

2021-01-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202000675(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-05-21 Application filed by Astellas Pharma Inc, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Astellas Pharma Inc

2013-05-21 Priority claimed from EP17171169.0A external-priority patent/EP3254695B1/en

2021-01-05 Publication of SMT202000675T1 publication Critical patent/SMT202000675T1/it

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Inorganic Chemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SM20200675T 2012-05-23 2013-05-21 Terapia di combinazione implicante anticorpi contro claudina 18.2 per il trattamento del cancro SMT202000675T1 (it)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/EP2012/002210 WO2013174403A1 (en)	2012-05-23	2012-05-23	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP17171169.0A EP3254695B1 (en)	2012-05-23	2013-05-21	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number	Publication Date
SMT202000675T1 true SMT202000675T1 (it)	2021-01-05

Family

ID=48483023

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SM20200675T SMT202000675T1 (it)	2012-05-23	2013-05-21	Terapia di combinazione implicante anticorpi contro claudina 18.2 per il trattamento del cancro
SM20240061T SMT202400061T1 (it)	2012-05-23	2013-05-21	Terapia di combinazione implicante anticorpi contro claudina 18.2 per il trattamento del cancro

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SM20240061T SMT202400061T1 (it)	2012-05-23	2013-05-21	Terapia di combinazione implicante anticorpi contro claudina 18.2 per il trattamento del cancro

Country Status (26)

Country	Link
US (2)	US20150132253A1 (it)
JP (2)	JP6203831B2 (it)
KR (4)	KR20250133804A (it)
CN (2)	CN104379166B (it)
AR (2)	AR091130A1 (it)
AU (2)	AU2013265638B2 (it)
BR (1)	BR112014028948B8 (it)
CA (1)	CA2874032A1 (it)
DK (2)	DK3791896T5 (it)
ES (3)	ES2971318T3 (it)
FI (1)	FI3791896T3 (it)
HR (2)	HRP20240169T1 (it)
HU (3)	HUE054214T2 (it)
IL (2)	IL235607A0 (it)
LT (3)	LT3254695T (it)
MX (5)	MX2014014216A (it)
NZ (2)	NZ725347A (it)
PL (1)	PL3791896T3 (it)
PT (3)	PT3791896T (it)
RS (2)	RS65179B1 (it)
RU (1)	RU2665321C2 (it)
SG (2)	SG11201406977TA (it)
SI (2)	SI3254695T1 (it)
SM (2)	SMT202000675T1 (it)
UA (1)	UA118013C2 (it)
WO (2)	WO2013174403A1 (it)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10254601A1 (de) *	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Antibodies useful in cancer diagnosis
WO2013174404A1 (en) *	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SI2852408T1 (sl)	2012-05-23	2017-10-30	Ganymed Pharmaceuticals Gmbh	Kombinacijska terapija, ki vključuje protitelesa proti claudin 18.2 za zdravljenje raka
WO2014075788A1 (en)	2012-11-13	2014-05-22	Biontech Ag	Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en)	2013-02-20	2014-08-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en)	2013-03-18	2014-09-25	Ganymed Pharmaceuticals Ag	Therapy involving antibodies against claudin 18.2 for treatment of cancer
US20170081723A1 (en) *	2014-03-21	2017-03-23	Agency For Science, Technology And Research	Fusion Genes in Cancer
CN107531787B (zh)	2015-01-27	2022-01-18	拉法医疗有限公司	靶向cd1d的单域抗体
WO2016180468A1 (en) *	2015-05-11	2016-11-17	Biontech Cell & Gene Therapies Gmbh	Claudin-18.2-specific immunoreceptors and t cell epitopes
CA3023143A1 (en)	2016-06-15	2017-12-21	Icahn School Of Medicine At Mount Sinai	Influenza virus hemagglutinin proteins and uses thereof
WO2018040537A1 (zh) *	2016-08-31	2018-03-08	南京凯地生物科技有限公司	人pd-1基因敲除的cldn18.2 特异性嵌合抗原受体t细胞的制备方法以及应用
WO2018119142A1 (en)	2016-12-21	2018-06-28	Amgen Inc.	Anti-tnf alpha antibody formulations
WO2018187706A2 (en)	2017-04-07	2018-10-11	Icahn School Of Medicine At Mount Sinai	Anti-influenza b virus neuraminidase antibodies and uses thereof
US10150801B1 (en)	2017-12-27	2018-12-11	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
EP3732190B1 (en) *	2017-12-27	2025-08-06	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
JP7398380B2 (ja)	2018-03-08	2023-12-14	フェインズセラピューティクス，インコーポレーテッド	抗クローディン１８．２抗体及びその使用
SG11202007074PA (en) *	2018-05-18	2020-08-28	Lanova Medicines Ltd Company	Anti-claudin 18.2 antibodies and uses thereof
EP3810634A4 (en)	2018-06-21	2022-07-27	Icahn School of Medicine at Mount Sinai	Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN110857322A (zh) *	2018-08-22	2020-03-03	瑞阳(苏州)生物科技有限公司	抗人claudin 18.2单克隆抗体及其应用
WO2020038404A1 (zh) *	2018-08-22	2020-02-27	瑞阳(苏州)生物科技有限公司	抗人claudin 18.2单克隆抗体及其应用
WO2020060406A1 (en)	2018-09-19	2020-03-26	Lava Therapeutics B.V.	Novel bispecific antibodies for use in the treatment of hematological malignancies
US20220033491A1 (en) *	2018-09-30	2022-02-03	Cafa Therapeutics Limited	Combination therapy of cldn18 antibody and chemotherapy drugs
CA3118696A1 (en) *	2018-11-08	2020-05-14	The Uab Research Foundation	Compositions and methods for treating cancer
CN113227146B (zh) *	2018-12-28	2024-03-01	南京金斯瑞生物科技有限公司	密蛋白18.2结合部分和其用途
US12297265B2 (en)	2018-12-28	2025-05-13	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Antibody and use thereof
MX2021011489A (es) *	2019-04-01	2021-10-22	Jiangsu Hengrui Medicine Co	Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
EP3959216A4 (en) *	2019-04-24	2023-01-11	Icahn School of Medicine at Mount Sinai	ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
WO2020238730A1 (zh) *	2019-05-24	2020-12-03	三优生物医药(上海)有限公司	新型cldn18.2结合分子
CN114026125B (zh) *	2019-07-12	2022-09-20	明济生物制药（北京）有限公司	Cldn18.2抗体及其用途
PE20211147A1 (es)	2019-08-12	2021-06-28	I Mab Biopharma Us Ltd	Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso
US10675332B1 (en)	2019-08-26	2020-06-09	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
CN114761433B (zh) *	2019-12-11	2025-07-29	上海复宏汉霖生物技术股份有限公司	一种抗Claudin18.2单克隆抗体、其制备方法及用途
WO2021198157A1 (en)	2020-03-30	2021-10-07	BioNTech SE	Rna compositions targeting claudin-18.2
CN116323667A (zh)	2020-07-08	2023-06-23	拉法医疗股份有限公司	结合PSMA和γ-δT细胞受体的抗体
WO2023025147A1 (zh) *	2021-08-23	2023-03-02	南通壹宸生物医药科技有限公司	抗原表位修饰
CN114907482B (zh) *	2021-09-03	2023-02-14	深圳市先康达生命科学有限公司	靶向人Claudin18.2蛋白的单克隆抗体及其应用
CN118139888A (zh) *	2021-11-05	2024-06-04	正大天晴药业集团股份有限公司	抗cldn18.2抗体及其用途
KR20240149438A (ko)	2022-02-27	2024-10-14	베링거 인겔하임 인터내셔날 게엠베하	Cd277 및 종양-항원에 대한 이중특이적 항체
WO2024074211A1 (en)	2022-10-06	2024-04-11	BioNTech SE	Rna compositions targeting claudin-18.2
CN120129702A (zh)	2022-10-06	2025-06-10	生物技术公司	靶向密蛋白-18.2的rna组合物
WO2024199673A1 (en)	2023-03-31	2024-10-03	Università Degli Studi Di Verona	Methods for predicting and improving therapeutic efficacy of cancer treatments and methods for cancer prognosis
WO2026033885A1 (en)	2024-08-08	2026-02-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
AR134560A1 (es)	2023-12-08	2026-01-28	Astellas Pharma Inc	Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120866A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2026062193A1 (en)	2024-09-20	2026-03-26	BioNTech SE	Compositions and methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5595756A (en) *	1993-12-22	1997-01-21	Inex Pharmaceuticals Corporation	Liposomal compositions for enhanced retention of bioactive agents
CN1487996B (zh)	2000-11-30	2010-06-16	米德列斯公司	用于生产人类抗体的转基因转染色体啮齿动物
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
CN101928344B (zh)	2002-10-17	2014-08-13	根马布股份公司	抗cd20的人单克隆抗体
KR20060134216A (ko) *	2004-04-16	2006-12-27	에미스페어 테크놀로지스, 인코포레이티드	활성제 전달을 위한 8-(2-히드록시페녹시)옥틸디에탄올아민및 그의 염
EP1930414B1 (en) *	2005-09-08	2012-07-18	Medinet Co., Ltd.	Method for activation treatment of antigen-presenting cell
EP1790664A1 (en) *	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) *	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2008152822A1 (ja) *	2007-06-15	2008-12-18	Medinet Co., Ltd.	医薬
AU2009209251B8 (en) *	2008-01-28	2015-03-26	Medimmune Limited	Stabilized Angiopoietin-2 antibodies and uses thereof
EP2316026A1 (en) *	2008-07-25	2011-05-04	Merck Patent GmbH	Method of determination of receptor binding saturation effected by monoclonal antibodies
WO2010141093A2 (en) *	2009-06-04	2010-12-09	The University Of Maryland, Baltimore	Co-signaling methods for treating cancers
WO2011090005A1 (ja) *	2010-01-19	2011-07-28	協和発酵キリン株式会社	大腸癌の治療用医薬および治療方法

2012
- 2012-05-23 WO PCT/EP2012/002210 patent/WO2013174403A1/en not_active Ceased
2013
- 2013-05-21 KR KR1020257028324A patent/KR20250133804A/ko active Pending
- 2013-05-21 KR KR1020247001045A patent/KR20240010757A/ko not_active Ceased
- 2013-05-21 PT PT201946258T patent/PT3791896T/pt unknown
- 2013-05-21 PT PT171711690T patent/PT3254695T/pt unknown
- 2013-05-21 LT LTEP17171169.0T patent/LT3254695T/lt unknown
- 2013-05-21 LT LTEP13724523.9T patent/LT2852408T/lt unknown
- 2013-05-21 DK DK20194625.8T patent/DK3791896T5/da active
- 2013-05-21 WO PCT/EP2013/001504 patent/WO2013174510A1/en not_active Ceased
- 2013-05-21 UA UAA201413810A patent/UA118013C2/uk unknown
- 2013-05-21 SG SG11201406977TA patent/SG11201406977TA/en unknown
- 2013-05-21 ES ES20194625T patent/ES2971318T3/es active Active
- 2013-05-21 RS RS20240147A patent/RS65179B1/sr unknown
- 2013-05-21 HU HUE17171169A patent/HUE054214T2/hu unknown
- 2013-05-21 SI SI201331818T patent/SI3254695T1/sl unknown
- 2013-05-21 PT PT137245239T patent/PT2852408T/pt unknown
- 2013-05-21 RU RU2014152115A patent/RU2665321C2/ru active
- 2013-05-21 FI FIEP20194625.8T patent/FI3791896T3/fi active
- 2013-05-21 CN CN201380026482.1A patent/CN104379166B/zh active Active
- 2013-05-21 PL PL20194625.8T patent/PL3791896T3/pl unknown
- 2013-05-21 BR BR112014028948A patent/BR112014028948B8/pt active IP Right Grant
- 2013-05-21 AU AU2013265638A patent/AU2013265638B2/en active Active
- 2013-05-21 ES ES17171169T patent/ES2835073T3/es active Active
- 2013-05-21 NZ NZ725347A patent/NZ725347A/en unknown
- 2013-05-21 SI SI201332076T patent/SI3791896T1/sl unknown
- 2013-05-21 KR KR1020147036040A patent/KR102233344B1/ko active Active
- 2013-05-21 DK DK13724523.9T patent/DK2852408T3/en active
- 2013-05-21 KR KR1020217006323A patent/KR102625189B1/ko active Active
- 2013-05-21 CA CA2874032A patent/CA2874032A1/en active Pending
- 2013-05-21 SM SM20200675T patent/SMT202000675T1/it unknown
- 2013-05-21 HR HRP20240169TT patent/HRP20240169T1/hr unknown
- 2013-05-21 HU HUE13724523A patent/HUE036000T2/hu unknown
- 2013-05-21 JP JP2015513044A patent/JP6203831B2/ja active Active
- 2013-05-21 ES ES13724523.9T patent/ES2637416T3/es active Active
- 2013-05-21 US US14/401,899 patent/US20150132253A1/en not_active Abandoned
- 2013-05-21 SG SG10201609772PA patent/SG10201609772PA/en unknown
- 2013-05-21 LT LTEP20194625.8T patent/LT3791896T/lt unknown
- 2013-05-21 MX MX2014014216A patent/MX2014014216A/es active IP Right Grant
- 2013-05-21 HU HUE20194625A patent/HUE065848T2/hu unknown
- 2013-05-21 RS RS20201449A patent/RS61127B1/sr unknown
- 2013-05-21 SM SM20240061T patent/SMT202400061T1/it unknown
- 2013-05-21 CN CN201811066117.4A patent/CN109172820B/zh active Active
- 2013-05-21 NZ NZ701585A patent/NZ701585A/en not_active IP Right Cessation
- 2013-05-22 AR ARP130101784 patent/AR091130A1/es not_active Application Discontinuation
2014
- 2014-11-10 IL IL235607A patent/IL235607A0/en active IP Right Grant
- 2014-11-21 MX MX2019013723A patent/MX2019013723A/es unknown
- 2014-11-21 MX MX2020011780A patent/MX2020011780A/es unknown
- 2014-11-21 MX MX2020011782A patent/MX2020011782A/es unknown
- 2014-11-21 MX MX2020011771A patent/MX2020011771A/es unknown
2017
- 2017-08-30 JP JP2017165303A patent/JP6490764B2/ja active Active
2018
- 2018-02-27 AU AU2018201391A patent/AU2018201391B2/en active Active
- 2018-03-01 US US15/909,577 patent/US20180258180A1/en not_active Abandoned
2020
- 2020-11-23 HR HRP20201859TT patent/HRP20201859T1/hr unknown
- 2020-12-09 IL IL279330A patent/IL279330A/en unknown
2022
- 2022-05-17 AR ARP220101320A patent/AR125906A2/es unknown

Also Published As

Publication number	Publication date
CA2874032A1 (en)	2013-11-28
MX2020011780A (es)	2020-11-24
KR102625189B1 (ko)	2024-01-16
MX2014014216A (es)	2015-06-23
RU2665321C2 (ru)	2018-09-04
IL279330A (en)	2021-01-31
PT3791896T (pt)	2024-02-12
PL3791896T3 (pl)	2024-05-13
ES2835073T3 (es)	2021-06-21
JP2015522543A (ja)	2015-08-06
JP2018035155A (ja)	2018-03-08
HRP20201859T1 (hr)	2021-04-02
AU2018201391A1 (en)	2018-03-22
HUE065848T2 (hu)	2024-06-28
LT3791896T (lt)	2024-03-12
RS65179B1 (sr)	2024-03-29
MX2019013723A (es)	2020-07-20
NZ725347A (en)	2018-07-27
BR112014028948B1 (pt)	2019-04-16
UA118013C2 (uk)	2018-11-12
SG10201609772PA (en)	2017-01-27
BR112014028948A2 (pt)	2016-10-25
RU2014152115A (ru)	2016-07-20
SI3791896T1 (sl)	2024-04-30
LT2852408T (lt)	2017-09-25
AR125906A2 (es)	2023-08-23
HK1208152A1 (en)	2016-02-26
US20150132253A1 (en)	2015-05-14
KR102233344B1 (ko)	2021-03-30
WO2013174510A1 (en)	2013-11-28
US20180258180A1 (en)	2018-09-13
HUE054214T2 (hu)	2021-08-30
AU2018201391B2 (en)	2019-12-05
SMT202400061T1 (it)	2024-03-13
PT2852408T (pt)	2017-08-25
SG11201406977TA (en)	2014-12-30
KR20150028777A (ko)	2015-03-16
KR20250133804A (ko)	2025-09-08
LT3254695T (lt)	2020-12-28
JP6203831B2 (ja)	2017-09-27
DK3791896T5 (da)	2024-08-19
SI3254695T1 (sl)	2021-01-29
CN104379166B (zh)	2018-10-12
CN109172820B (zh)	2023-06-20
AR091130A1 (es)	2015-01-14
AU2013265638B2 (en)	2018-03-01
PT3254695T (pt)	2020-12-11
JP6490764B2 (ja)	2019-03-27
ES2971318T3 (es)	2024-06-04
ES2637416T3 (es)	2017-10-13
AU2013265638A1 (en)	2014-11-20
KR20240010757A (ko)	2024-01-24
FI3791896T3 (fi)	2024-02-01
BR112014028948A8 (pt)	2018-12-26
WO2013174403A1 (en)	2013-11-28
NZ701585A (en)	2016-10-28
BR112014028948B8 (pt)	2019-09-03
KR20210025730A (ko)	2021-03-09
DK2852408T3 (en)	2017-09-11
CN109172820A (zh)	2019-01-11
IL235607A0 (en)	2015-01-29
RS61127B1 (sr)	2020-12-31
CN104379166A (zh)	2015-02-25
MX2020011782A (es)	2020-11-24
MX2020011771A (es)	2020-11-24
DK3791896T3 (da)	2024-02-12
HUE036000T2 (hu)	2018-06-28
HRP20240169T1 (hr)	2024-04-26

Publication	Publication Date	Title
IL279330A (en)	2021-01-31	Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
IL276434A (en)	2020-09-30	Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
IL239981A0 (en)	2015-08-31	Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer
IL240060A0 (en)	2015-09-24	Treatment involving antibodies against claudin 2. 18 for the treatment of cancer
SI2804599T1 (sl)	2019-05-31	Kombinirana terapija za zdravljenje raka
PL3254695T3 (pl)	2021-04-06	Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu
IL263781A (en)	2019-01-31	Combined treatment of ovarian cancer
SMT202200458T1 (it)	2023-01-13	Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
PL2976360T3 (pl)	2020-05-18	Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego
IL233495A0 (en)	2014-08-31	Combination for cancer treatment